Chronic Heart Failure Clinical Trial
— HRVFIT2Official title:
Efficacy of High Intensity Interval Training vs Moderate Intensity and Continuous Training on Autonomic Nervous System Modulations in Chronic Heart Failure
NCT number | NCT03603743 |
Other study ID # | 2-15-12 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 7, 2015 |
Est. completion date | October 13, 2017 |
Verified date | July 2018 |
Source | Cardiovascular and Pulmonary Rehabilitation Center of Saint Orens |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Purpose: Exaggerated sympathetic nervous system (SNS) activity associated with low heart rate variability (HRV) is considered as a trigger of cardiac arrhythmias and sudden death. Regular exercise training is efficient to improve autonomic balance. In 2013, the investigators published that a single session of an optimized short-high intensity interval exercise with passive recovery (HIIT) protocol was efficient in chronic heart failure (CHF) patients for enhancing vagal tone and to decrease arrhythmias in the 24-h post exercise period when compared to a single session of moderate intensity continuous exercise (MICT). Nevertheless the effects of HIIT training performed on several weeks have never yet been studied on the parameters described by Coumel's triangle (the arrhythmogenic substrate, the trigger factor as premature ventricular contraction and the modulation factors of which the most common is the autonomic nervous system). The aim of this study was to verify the superiority of HIIT to enhance parasympathetic activity, cardiorespiratory fitness and cardiac function when compared to MICT in a short and intense cardiac rehabilitation program.
Status | Completed |
Enrollment | 32 |
Est. completion date | October 13, 2017 |
Est. primary completion date | October 13, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - stable chronic heart failure with NYHA functional class from I to III - stable left ventricular ejection fraction (LVEF) < 45% over at least 6 months - stable optimal medical therapy including a beta-blocker and an angiotensin-converting enzyme inhibitor or angiotensin receptor blockers for at least 6 weeks - ability to perform a maximal cardiopulmonary exercise test - admitted to the Rehabilitation Centre for a comprehensive Cardiovascular Rehabilitation Program Exclusion Criteria: - any relative or absolute contraindications to exercise training according to current recommendations - fixed-rate pacemaker with heart rate limits set lower than exercise training target - major cardiovascular event or procedure within the 3 months preceding enrolment - chronic atrial fibrillation - heart failure secondary to significant uncorrected primary valve disease (except for mitral regurgitation secondary to left ventricular dysfunction) - heart failure secondary to congenital heart disease or obstructive cardiomyopathy. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cardiovascular and Pulmonary Rehabilitation Center of Saint Orens | Clinique Pasteur, Institut National de la Santé Et de la Recherche Médicale, France, University Hospital, Toulouse |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | High Frequency power in normalized units (HFnu%) | based on Heart Rate Variability, the power spectral density of the HF (0.15-0.40 Hz, ms2.Hz-1) bands were calculated. | Change from baseline through study completion, an average of 4 weeks (measured during the night period for stationary signal) | |
Secondary | maximal oxygen consumption (VO2peak ml.min.kg) | VO2 at peak exercise was measured with Cardiopulmonary Exercise Test. | Change from baseline through study completion, an average of 4 weeks | |
Secondary | First ventilatory threshold (VT1) (ml.min.kg) | VO2 at VT1 was measured with Cardiopulmonary Exercise Test. | Change from baseline through study completion, an average of 4 weeks | |
Secondary | Heart Rate Recovery (beats per minute, bpm) | Heart Rate Recovery (with passive recovery) at 1, 2 and 3 minutes after peak exercise (in beats per minute, bpm) | Change from baseline through study completion, an average of 4 weeks | |
Secondary | Left Ventricular Ejection Fraction (LVEF, %) | LV volumes and ejection fraction were calculated from apical recordings by modified biplane Simpson's method. | Change from baseline through study completion, an average of 4 weeks | |
Secondary | premature ventricular contraction, (n/24h) | Ectopic ventricular beats were classified as isolated premature contractions, bigeminy, and salves. | Change from baseline through study completion, an average of 4 weeks | |
Secondary | NT-pro-BNP, (ng/L) | blood sample analysis | Change from baseline through study completion, an average of 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03597646 -
The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure
|
N/A | |
Terminated |
NCT04065997 -
Apogee International
|
||
Withdrawn |
NCT03675113 -
Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02916160 -
Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
|
Phase 4 | |
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Completed |
NCT02247245 -
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
|
N/A | |
Completed |
NCT02268500 -
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
|
Phase 4 | |
Terminated |
NCT01906957 -
Cognition and Exercise Training
|
N/A | |
Completed |
NCT01919918 -
Muscle Afferent Feedback Effects in Patients With Heart Failure
|
Phase 1 | |
Not yet recruiting |
NCT01669395 -
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
|
N/A | |
Completed |
NCT00984529 -
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
|
N/A | |
Recruiting |
NCT00863421 -
Sleep Disordered Breathing in Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02840565 -
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
|
Phase 1 | |
Completed |
NCT02441218 -
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
|
Phase 3 | |
Completed |
NCT00149409 -
Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT05532046 -
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
|
Phase 1 | |
Recruiting |
NCT04984928 -
Readmission Risk of Patients With Heart Failure.
|
||
Completed |
NCT02814097 -
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Active, not recruiting |
NCT05560737 -
ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
|
||
Recruiting |
NCT03286127 -
Palliative Outcome Evaluation Muenster I
|